

May 17, 2023

The Honorable Drew Ferguson
U.S. House of Representatives
1032 Longworth House Office Building
Washington, DC 20515

The Honorable Scott Peters
U.S. House of Representatives
1201 Longworth House Office Building
Washington, D.C. 20515

The Honorable Jake LaTurner
U.S. House of Representatives
1630 Longworth House Office Building
Washington, DC 20515

The Honorable Mike Levin
U.S. House of Representatives
2352 Rayburn House Office Building
Washington, D.C. 20515

Dear Representatives Ferguson, LaTurner, Peters and Levin

On behalf of Vizient, Inc., I am pleased to offer our endorsement for H.R.2940, the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2023. Your important, bipartisan legislation would encourage investment in the development of drugs to address antimicrobial resistance.

Vizient is the nation's largest healthcare performance improvement company. Vizient provides solutions and services that improve the delivery of high-value care by aligning cost, quality, and market performance for more than 60% of the nation's acute care providers, which includes 97% of the nation's academic medical centers and more than 25% of ambulatory providers. Vizient provides expertise, analytics, and advisory services, as well as a contract portfolio that represents more than \$130 billion in annual purchasing volume, to improve patient outcomes and lower costs. Headquartered in Irving, Texas, Vizient has offices throughout the United States.

The PASTEUR Act would establish a subscription program that would support the development of critically needed antimicrobial drugs. This program would provide upfront revenue commitments to drug manufacturers in exchange for access to innovative drugs to treat and improve clinical outcomes for those with resistant infections, and support future research to prevent drug-resistant infections. The legislation will also provide important support for hospitals and other healthcare providers to implement programs at their facilities to improve judicious use of antimicrobial drugs and adopt programs that may improve reporting and clinical outcomes

Thank you for your leadership in introducing this bill. Antimicrobial resistance is significant and growing problem. Your legislation would take important steps to promote innovation and slow the growth of drug-resistant infections. We are pleased to support this legislation and encourage its swift passage.

Thank you again and please do not hesitate to contact me at shoshana.krilow@vizientinc.com or 202-354-2607 if you have any questions about Vizient or if there is any way we can be of assistance in advancing your important legislation.

Sincerely,



Shoshana Krilow
Senior Vice President, Public Policy & Government Relations

May 17, 2023

The Honorable Michael Bennet
U.S. Senate
261 Russell Senate Building
Washington, DC 20510

The Honorable Todd Young
U.S. Senate
185 Dirksen Senate Office Building
Washington, D.C. 20510

Dear Senators Bennet and Young,

On behalf of Vizient, Inc., I am pleased to offer our endorsement for S.1355, the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2023. Your important, bipartisan legislation would encourage investment in the development of drugs to address antimicrobial resistance.

Vizient is the nation's largest healthcare performance improvement company. Vizient provides solutions and services that improve the delivery of high-value care by aligning cost, quality, and market performance for more than 60% of the nation's acute care providers, which includes 97% of the nation's academic medical centers and more than 25% of ambulatory providers. Vizient provides expertise, analytics, and advisory services, as well as a contract portfolio that represents more than \$130 billion in annual purchasing volume, to improve patient outcomes and lower costs. Headquartered in Irving, Texas, Vizient has offices throughout the United States.

The PASTEUR Act would establish a subscription program that would support the development of critically needed antimicrobial drugs. This program would provide upfront revenue commitments to drug manufacturers in exchange for access to innovative drugs to treat and improve clinical outcomes for those with resistant infections, and support future research to prevent drug-resistant infections. The legislation will also provide important support for hospitals and other healthcare providers to implement programs at their facilities to improve judicious use of antimicrobial drugs and adopt programs that may improve reporting and clinical outcomes

Thank you for your leadership in introducing this bill. Antimicrobial resistance is significant and growing problem. Your legislation would take important steps to promote innovation and slow the growth of drug-resistant infections. We are pleased to support this legislation and encourage its swift passage.

Thank you again and please do not hesitate to contact me at shoshana.krilow@vizientinc.com or 202-354-2607 if you have any questions about Vizient or if there is any way we can be of assistance in advancing your important legislation.

Sincerely,



Shoshana Krilow
Senior Vice President, Public Policy & Government Relations